CEBPZ and acute myeloid leukemia: On the other hand, 29 patients (59%) received HMAs as second-line or more (after failure of intensive chemotherapy, for R/R CBF-AML), with a median time from diagnosis to HMA treatment of 476 days (range 104–5393) (Table 1).